Mestag harnesses new insights into fibroblast immunology to develop impactful treatments for patients with cancer and inflammatory diseases. We are progressing a unique pipeline of novel antibodies designed to direct and drive the immune system using known and emerging fibroblast-immune biology.
Mestag Therapeutics
Mestag Therapeutics
- Life Sciences
- Cambridge, United Kingdom
- £30m
- mestagtherapeutics.com
- Update Information
More venture news
- 5 Aug 2026
MironidMironid raises a £34m Series B including £8.4m from Scottish National Investment Bank to advance small molecule treatments for kidney diseases
Series BLife Sciences - 29 Jul 2026
QureightQureight lands £15m Series B led by Molten Ventures to bring AI imaging to clinical trials for lung and heart disease
Series BLife Sciences - 7 Jul 2026
Healome TherapeuticsHealome Therapeutics raises £2m to advance eye-drop matrix technology treating dry eye and ocular surface disease
SeedLife Sciences